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Figen Amber Cicek, Hilmi B Kandilci and Belma Turan*Background: The RhoA/ROCK signaling pathway mediates vascular smooth muscle contraction while endogenous
NO induces vasodilation through its inhibition. Since myosin light chain phosphatase (MLCP) and eNOS are
targeted by RhoA/ROCK upregulation then turn to lead abnormalities in vasculature, we aimed to examine whether
less endothelial NO-production and inhibited eNOS together with an upregulation of RhoA/ROCK signaling
pathway in thoracic aorta can play an important role in vascular dysfunction under hyperglycemia.
Methods: We used streptozotocin-injected rats, as a model of type 1 diabetes, and their lean controls to
investigate the role of ROCK upregulation in the function of toracic aorta by using electrophysiological and
biochemical techniques.
Results: The protein level of ROCK isoform ROCK2 was found to be 2.5-fold higher in endothelium-intact aortic
rings of the diabetic rats compared to those of the controls while its level in endothelium-denuded rings was
similar among these two groups. Phosphorylation level of eNOS in endothelium-intact rings from the diabetics was
50% less compared to that of the control. ROCK inhibitors, either Y27632 or HA1077, induced concentration-
dependent relaxation with a marked left-shift in phenylephrine pre-contracted endothelium-intact rings from either
diabetics or high glucose incubated controls while pretreatment of these rings with L-NAME abolished this shift,
fully. Moreover, phosphorylation levels of both MLCP and MLC in endothelium-denuded rings were markedly
higher in the diabetics than the controls.
Conclusion: We demonstrated that diabetes-induced vascular dysfunction can arise due to either inbition of eNOS,
thereby less endothelial NO-production, either directly or indirectly, in part, due to an upregulation of ROCK2 by
hyperglycemia. Additionally, our data demonstrate that high phosphorylation levels of both MLC and MLCP in
endothelium-denuded rings can be due to a less endothelial NO-production dependent ROCK upregulation in the
smooth muscle cells under hyperglycemia, as well.
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Type 1 diabetes mellitus is characterized by severe
hyperglycemia at the whole body as well as several ser-
ious functional and structural alterations in the myocar-
dium and vasculature. Endothelial vascular dysfunction
plays a key role in the pathogenesis of cardiovascular
disorders in diabetes [1,2]. Endothelium controls the
tone of the underlying vascular smooth muscle cells
through NO-production during physiological and patho-
logical conditions, as well. Previous studies, supporting* Correspondence: belma.turan@medicine.ankara.edu.tr
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reproduction in any medium, provided the orthis statement properly, have shown that there is an
association between glucose-induced damage in endo-
thelial cells and decreased NO-bioavailability in the vas-
cular bed [3-5].
The underlying mechanisms of altered contractile re-
sponsiveness of vascular smooth muscle cells in diabetes
are generally considered to be related to either impaired
endothelium-dependent vasorelaxation or to an alteration
in the contractility of vascular smooth muscle itself, or
both. Accordingly, numerous studies have demonstrated
also that diabetes impairs vascular function via inhibition
of the endothelium-dependent vasodilatation, accompan-
ied by selective impairment of NO-dependent componenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dilatation in arteries is due to an activation of MLCP in a
cGMP-dependent manner while MLCP inactivation via
RhoA/Rho-kinase (ROCK) pathway antagonizes this
Ca2+-desensitizing effect [7]. In diabetic preparations,
an involment of ROCK-pathway in the mechanical ac-
tivity of arteries via an increase in active RhoA-kinase
level and decreases in both eNOS expression and NO-
production by endothelium has been shown already
with the previously published data [8,9]. Indeed, in a
very recent study, authors determined the role of ROCK
isoforms in diabetes-induced vascular endothelial dysfunc-
tion and demonstrated that there is a close association be-
tween a reduction in endothelial NO-production and
upregulation of ROCK while limiting ROCK activity im-
proves vascular function in type 1 diabetic mice [10].
Although several different factors likely play important
role in the development of diabetes-associated abnormal
vascular reactivity, diabetes-induced altered regulation of
smooth muscle cell contraction is particularly through a
regulation by the opposing activities of myosin light
chain kinase (MLCK) and myosin light chain phosphat-
ase (MLCP) [11]. Indeed, it is well accepted that MLCP
can be inhibited via a pathway that involves RhoA/
ROCK signaling. This pathway can induce phosphoryl-
ation of myosin phosphatase target subunit 1 (MYPT1),
a subunit of MLCP, which in turn inhibits MLCP activity
[12]. Moreover, Wang et al. [13] showed that two
isoforms of ROCK (1 and 2) are expressed in vascular
smooth muscle cells, and both inhibit MLCP activity al-
though an isoform-specific role in vascular system al-
though a mechanism of ROCK-mediated regulation of
MLC phosphorylation, in part due to eNOS level is not
well understood yet. Therefore, we aimed to examine
the role of ROCK isoforms and involvement of eNOS
(indirectly endothelial NO-production) and MLCP activ-
ity as well as their association with hyperglycemia in
endothelium-dependent and -independent reactivity of
thoracic aorta from diabetic rats.
Materials and methods
Induction of type 1 diabetes in rats
All animal care and experimental procedure were
performed by following Ankara University ethics guide-
lines (No: 2007-11-39). Diabetes was induced in 3-
month-old male Wistar rats as described previously [14].
Shortly, diabetes was induced by a single intraperitoneal
injection (i.p.) of streptozotocin (STZ, 50 mg/kg body
weight and dissolved in 0.1 M citrate buffer, pH 4.5) in
the rats (200–250 g initial body weight). Control rats re-
ceived citrate buffer alone. A week after injection of
STZ, blood glucose levels were measured and rats with
blood glucose at least 3-fold higher than the pre-
injection level were used as diabetic rats. All rats hadfree access to standard rat chow and water, and they
were kept for 4 weeks more following the induction of
diabetes (totally 5 weeks).
Histological examination
Histological examination was performed as described
previously [14]. For histological examination, aortic rings
were fixed in phosphate buffer containing 10% formalde-
hyde for 2 days. Following sample dehydration through
graded alcohol concentrations (50%, 75%, 96% and
100%), the aorta tissue was embedded into paraffin. The
embedded samples were sliced at a thickness of 4–6 μm
using a Leitz-1512 microtome. Sections were stained
with hematoxylin and eosin. Images were obtained by
using a Zeiss Axioscope photomicroscope coupled to a
charge-coupled device (CCD) camera and analyzed by
using color threshold (for collagen and elastin contents).
Measurement of relaxation responses of aortic
preparations
Aortic rings were prepared as described previously [15].
The rings were set at 1-g passive tension and allowed to
equilibrate for 60 min, and then first their contractile
ability was assessed by exposure to 60 mM KCl.
Endothelium-denuded (endo-) or -intact (endo+) rings
were pre-contracted with 1-μM phenylephrine (Phe) in
absence or presence of N(G)-nitro-L-arginine methyl
ester (L-NAME), and treated with increasing concentra-
tions of a ROCK2 inhibitor Y27632 (10-9 - 10-5 M). For
comparison, we used another inhibitor HA1077 (10-9 -
10-5 M). Some endo(−) rings were treated with Y27632
before contraction and then relaxed with NO donor so-
dium nitroprusside, SNP.
To mimic diabetes, aortic rings from control rats were
incubated with either only DMEM (5.5-mM glucose)
(Biological Industries, Israel) or high glucose (40-mM)
containing DMEM for overnight. Following the incuba-
tion period, relaxation responses to Y27632 were mea-
sured following 1-μM Phe-precontraction.
Western blot analysis
The frozen aortas were pulverized at liquid nitrogen
temperature and then homogenized as described previ-
ously [14]. ROCK1/2, eNOS and phospho-eNOS, MLC
and phospho-MLC, MYPT1 and phospho-MYPT1 pro-
tein levels were determined by using Western blotting.
The samples were homogenized in ice cold homo-
genization buffer (20 mM Tris–HCl at pH 7.4), 150 mM
NaCl, 2 mM KCL, 2 mM EDTA, 0.5 mM DTT, 100 mM
protease inhibitor cocktail. The homogenate was clari-
fied by centrifugation at 1000 g for 10 min at 4°C, the
supernatant was collected and protein concentration was
measured with Bradford assay by using BSA as a stand-
ard protein. The PVDF membranes were incubated
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(1:500, Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), MYPT1 or phosphospecific MYPT1 (Thr853) anti-
bodies (1:200, Cell Signaling Technology, Inc., Danvers,
MA, USA), eNOS or phosphospecific eNOS (Ser 1177),
and MLC or phosphospecific MLC antibodies (1:500,
Abcam, Cambridge MA, USA) at 4°C, β-actin (1:1000,
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
antibody was used to control the equal amount loading.
Chemicals, data analysis and statistics
Unless specified, the reagents used were obtained from
Sigma-Aldrich Canada or Fisher Scientific.
Data are presented as mean ± SEM. Concentration-
response curves and the negative logarithm of half max-
imal effective concentration (Log IC50) were obtained by
using spline fit (curve fitting) with GraphPad Prism (ver-
sion 5.01). Student t-test or one-way ANOVA followed
by tukey-test were used to determine statistical signifi-
cance (at p < 0.05).
Results
Effect of diabetes on general characteristics of rats and
thoracic aorta
Five weeks after STZ injection, rats from diabetic group
(DM) showed significant increase in water consumption,Figure 1 Effects of diabetes on the structure and contractile function
thoracic aorta. Micrographs of the transverse aortic sections in the control
diameter of the aorta in the diabetic group compared to that of the contro
(C), and the diabetic group (D). Dark dense part tunica media containing m
adventisia containing collagen deposition. Trichrome x40. (E) Original trace
treated aorta rings from control (top left), L-NAME incubated control (botto
(bottom right) groups. (F) The maximum responses to the Phe. Bars repres
(by using ANOVA with Tukey test).blood glucose level (432 ± 8.6 mg/dL and 110 ± 4.8 mg/
dL in DM vs. CON) with marked reduction in body
weight (195 ± 6.8 g) compared to those of the controls
(241 ± 9.8 g).
Significant thickening of smooth muscle bundle in the
total wall was observed in the aorta from diabetic rats al-
though there was no significant change in the internal
diameter of aortas from the diabetic and the control
groups (Figure 1A and B, respectively). Observed basic
histological differences in the aorta structure among the
control and the diabetic rats are illustrated in Figure 1C
and D, respectively. More and better organized smooth
muscle cell layers (light pink) in the aorta of the control
group were seen between the elastin bundles (dark pink).
However, significant thickening of the total aortic wall
was observed in the diabetic rats. As published previ-
ously [14,16,17], in here, the thickness of the collagen
deposition in diabetics was increased as about 3.5-fold
compared to that of the control.
Effect of diabetes on contractile responses to
phenylephrine application
We previously demonstrated that STZ-diabetic rats
exerted a marked vascular endothelial and contractile
dysfunctions including impaired contractile responses to
1-μM Phe or KCl and impaired endothelium-dependentof thoracic aorta. Light microscopy of endothelium-denuded
group (A), and the diabetic group (B). Note the unchanged internal
l (H. E. X4). Masson’s trichrome stained aorta from the control group
ostly smooth muscle cells and elastin, slightly dense part tunica
s representing isotonic contraction of phenylephrine (Phe; 1-μM)
m left) and diabetic (top right) and L-NAME incubated diabetic
ent mean ± SEM; n = 6–8 aortic rings/group. *P < 0.05 vs. CON
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cations. In here, we first examined the contractile activ-
ity in absence or presence of L-NAME in STZ-diabetic
rings. Aortic rings isolated from diabetic rats presented
a less contractile response to the Phe application com-
pared to that of the control under either absence or
presence of L-NAME (Figure 1E). As illustrated in
Figure 1F, the maximal responses to Phe-precontraction
in the either diabetic group or control group in the pres-
ence of L-NAME are not significantly different from
those of absence of L-NAME. Our first data with dia-
betics can provide a first information related with
diabetes-induced a contractile vascular function, of
which showed, that contractions in response to phenyl-
ephrine were not effected from NO-release in diabetic
rat aortic rings [14,15,18].
Effect of diabetes on eNOS protein level in endothelium-
intact thoracic aorta
In order to demonstrate an involvement of ROCK-
pathway via a change in eNOS protein expression level
and endothelial NO-production in the aorta from STZ-
diabetic rats [8,9], we measured eNOS protein level and
its total phosphorylation level in endothelium-intact
(endo+) rings (Figure 2A to C). The bars (in Figure 2B
and C) are obtained with a normalization of the eNOS
protein bands to β-actin protein bands. As can be seenFigure 2 The phospho/total eNOS and Rho-kinases1/2 (ROCK1/2) pro
phospho-eNOS (at Ser 1177), eNOS (140 kDa) and β-actin protein expressio
homogenates. (B) Left axis, eNOS and right axis phospho-eNOS was norma
normalized to corresponding eNOS protein band (D) and (E) Representativ
endothelium denuded and endothelium intact aorta homogenates from co
mean ± SEM are representing ROCK1 and ROCK2 protein levels which were
group (by using student t-test).from Figure 2B, the total eNOS protein level in diabetic
group was significantly higher than that of the corre-
sponding control group while the phospho-eNOS values
were similar among these two groups. Therefore, the
phospho-eNOS (at Ser 1177) to total eNOS ratio was
found to be decreased as about 50% in the diabetic
group compared to that of the control group (Figure 2C).
This ratio confirms a decrease level of endothelial NO-
production in endo(+) rings from diabetics, which can
further induce a functionally inactive endothelial layer in
these preparations.
RhoA through ROCK effectors in isolated thoracic aorta:
ROCK1 and ROCK2
In order to demonstrate a role of ROCK isoforms in
diabetes-induced vascular dysfunction, we first examined
the protein levels of ROCK1 and ROCK2 in both endo
(−) and endo(+) aortic rings from both groups of rats
(Figure 2C and D, respectively).
Upper parts of Figure 2D and E show the relative level of
every substance/β-actin, quantified by using a bioimage
analyzer. As shown with bar graphs, the relative protein
levels of ROCK1 in both endo(−) and endo(+) aortas did
not differ significantly between the diabetic and the control
groups. However, the relative protein level of ROCK2 in
the endo(+) aortic rings, but not in the endo(−) prepara-
tions from the diabetic group was significantly higher thantein levels in diabetic rat thoracic aorta. (A) Blotting data for
ns from the control (CON) and the diabetic (DM) rat aorta
lized to corresponding β-actin protein band. (C) Phospho-eNOS was
e Western Blots of 160 kDa ROCK1, and 150 kDa ROCK2 of
ntrol (CON) and diabetic (DM) rats, respectively. Bar graphs, as
normalized to β-actin, n = 5 homogenates/group, *P < 0.05 vs. CON
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ated with the increased ROCK2 protein level which can
provide also an important information related with pos-
sible correlation between the increased level of ROCK2 ex-
pression in the endothelium and a functionally inactive
endothelial layer in the aortic rings from STZ-diabetic rats.
Effect of ROCK inhibition on Phe-precontraction and
relaxation responses in the endo(+) and endo(−) aortic
rings
To test possible contribution of ROCK signaling path-
way into hyperglycemia-induced impaired relaxation re-
sponses, we first treated diabetic endo(+) rings with
ROCK2 inhibitor, 1-μM Y27632 and then they were
contracted with 1-μM Phe. As can be seen from Figure 3-
A, the contractile response to the Phe in ROCK2
inhibitor-incubated endo(+) diabetic rings is much more
smaller that of untreated and control ones (the last data
not shown). In a further experiment with endo(−) dia-
betic aortic rings either treated with Y27632 or not, their
concentration-dependent contractile responses to Phe
(10-9 – 10-4 M) are overlapped fully (Figure 3B).
In another set of experiments, either the endo(+) or
endo(−) diabetic aortic rings were first contracted withFigure 3 Effect of ROCK inhibition on Phe-precontraction and relaxat
presence of 1-μM Y27632, the contractile response to 1-μM Phe stimulation
that of without Y27632. (B) The concentration-dependent contractile respo
presence of 1-μM Y27632 are overlapped. Data are expressed as mean ± SE
student t-test). (C) DM endo(+) exhibited an increased vasodilator sensitivit1-μM Phe and exposed to increasing concentrations of
Y27632. The endo(+) rings compared to the endo(−)
ones exhibited markedly increased vasodilator sensitivity
to Y27632 compared to those of the endo(−) rings
(Figure 3C).
Effect of NO-synthase inhibition on relaxation to ROCK
inhibitor in diabetic rat thoracic aorta
To test effect of diabetes on relaxation to ROCK inhib-
ition, the endo(+) rings were first precontracted with
1-μM Phe and then were relaxed with Y27632 (from
10-9 to 10-5 M) either in absence or presence of L-NAME.
As shown in Figure 4A, the aortic rings from diabetics
exhibited increased vasodilator sensitivity to Y27632 com-
pared to those of the controls. In presence of L-NAME,
ROCK inhibition was significantly less effective in both
diabetic and control groups (Figure 4A). The Log [IC50]
value for the relaxation to 1-μM Y27632 in diabetics
(−6.684 ± 0.08) is significantly smaller than that of control
(−6.02 ± 0.05), whereas these are found to be similar be-
tween these two groups with the presence of L-NAME.
For comparison, we measured relaxation responses with
another ROCK inhibitor, HA1077. The relaxation re-
sponses to 1-μM HA1077 in diabetics were also exhibitedion responses in the endo(+) and endo(−) aortic rings. (A) In the
in diabetic (DM) endo(+) aortic rings was markedly less compared to
nses to Phe of diabetic endo- aortic rings, either in the absence or
M, n = 5-6/group. *P < 0.05 vs. without Y27632 samples (by using
y to Y27632 compared with endo(−) aortic rings.
Figure 4 Effect of NO synthase inhibition with L-NAME on the relaxation response to Y27632 in the precontracted endo(+) aortic rings.
(A) DM endo(+) aortic rings were exhibited an increased vasodilator sensitivity to Y27632 compared with control (CON) aortic rings. In the
presence of L-NAME, ROCK inhibition was less effective to both DM and CON groups. Log [IC50] values on the relaxation to Y27632 are given in
the inset. (B) Hyperglycemic (HG) endo(+) aortic rings were also exhibited an increased vasodilator sensitivity to Y27632 compared with CON
aortic rings. Their Log [IC50] values on the relaxation to Y27632 are given in the inset. (C) Effect of ROCK inhibition on relaxation response to SNP
after submaximal contraction with 1-μM Phe in endo(−) aortic rings were presented. In the presence of Y27632 an increased and equivalent
vasodilatory sensitivity to SNP was observed for both DM and CON aortic samples. The Log [IC50] values for the relaxation to SNP are given in the
inset. Data are expressed as mean ± SEM, n = 5-6/group. *P < 0.05 vs. CON group, by using student’s t test.
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the controls (data not shown). The Log [IC50] value of the
diabetics in the presence of L-NAME (−5.3 ± 0.2) is sig-
nificantly greater than that of Log [IC50] in the absence of
L-NAME (−5.9 ± 0.2).
For assessment of diabetes-induced relaxation dysfunc-
tion to ROCK inhibition, we performed some experiments
with high glucose-incubated rings. Incubation of rings
with either 40-mM glucose for overnight exhibited an in-
creased vasodilator sensitivity to 1-μM Y27632 application
compared to normal glucose (5.5-mM)-incubated con-
trols. The Log [IC50] values are measured as −6.344 ± 0.07
and −6.02 ± 0.05, respectively (Figure 4B). In the presence
of L-NAME, similar to the diabetic group, ROCK inhib-
ition was significantly less effective in both high-glucose
incubated or normal-glucose-incubated control groups
(Figure 4B).
Effect of Y27632 on endothelial NO-induced relaxation in
diabetic rat aorta
To examine the effect of ROCK inhibition on the relax-
ation response to NO, endothelium-denuded rings were
first contracted with 1-μM Phe (in the absence or pres-
ence of 1-μM Y27632) and subsequently relaxed with in-
creasing concentrations of sodium nitroprusside, SNP(10-13–10-7.5 M), a NO donor [19]. Compared with un-
treated rings, rings treated with 1-μM Y27632 before
Phe-precontraction exhibited an increased vasodilator
sensitivity to SNP (Figure 4C). This result can suggest
that inhibition of ROCK potentiates endothelial NO-
induced relaxation. It is important to note that treat-
ment with 1-μM Y27632 did not augment significantly
the contractile response in endothelium-denuded rings.
These data are in line with a fact of altered relaxation re-
sponses to ROCK inhibition in diabetic samples are
mostly due to endothelial dysfunction.
Effect of diabetes on increased phosphorylations of MLCP
and MLC in thoracic aorta
A substrate of ROCK is MLCP, which is physiologically
responsible for dephosphorylation of MLC [20]. There-
fore, MLCP phosphorylation is a hallmark of ROCK acti-
vation [21] which can also phosphorylate MLC directly
[22]. To test this pathway in smooth muscle cells from
the diabetic rat aortic rings, phosphorylation level of
MLCP (phospho-MYPT1) was evaluated. The endo(−)
aortic rings from diabetic rats showed no change in the
protein level of MYPT1 compared to those of the con-
trols whereas its phosphorylation level was markedly
higher in the diabetic preparations (Figure 5A to C). As
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total MYPT1 ratio of the diabetics is significantly higher
than that of the control.
Since inactivation of MLCP is associated with in-
creased phospho-MLC, and a net effect of ROCK activa-
tion is associated with increased phospho-MLC, we
found that phospho-MLC was found to be markedly
higher in diabetics compared to that of control with no
change in its protein level. Furthermore, phospho-MLC
to total MLC ratio for diabetic endo(−) aortic rings is
significantly higher than that of control (Figure 5E to H).
These results indicate that the depressed contractile
activity of the aortic rings in diabetics includes, in part, a
ROCK inhibition in the smooth muscle cells.
Discussion
Our data provides new information related with associ-
ation between important role of RhoA/ROCK pathway
via depressed eNOS due to less endothelial NO-
production and impaired mechanical activity of aorta
under hyperglycemia. The histological data based on the
observed aortic stiffness as an indication of thickening of
smooth muscle bundle in the total wall structure seem
to be closely associated with the observed impaired
mechanical activity. Previous studies, similar to ours
demonstrated a similar association what is observed in
vascular preparations which are strongly supporting the
present results also [17,23,24]. Parallel to this fact, we
showed that the significant decrease in the total protein
level of eNOS, a strong marker of endothelial dysfunc-
tion via less endothelial NO-production level [10],
is associated with impaired structural and functionalFigure 5 Phospho/total MYPT1 and Phospho/total MLC expressions in
MYPT1, MYPT1 (140 kDa) and β-actin expressions from control (CON) and d
MYPT1 normalized to β-actin. (D) Phospho-MYPT1 was normalized to corre
Western Blots for phospho-MLC, MLC (20 kDa) and β-actin (43 kDa) express
(G) Phospho-MLC normalized to the β-actin. (H) Phospho-MLC was norma
mean ± SEM, n = 5 homogenates/group, *P < 0.05 vs. CON group (by usingproperties of endo(+) diabetic aortas. Depressed con-
tractile responses of diabetic endo(+) aortas, with either
absence or presence of L-NAME, consistent with
diabetes-induced both endothelial and smooth muscle
dysfunction, which seems to be, in part, associated with
structural alterations also. In addition, although there
was no differences between relaxation responses of Phe-
precontracted diabetic and control endo(−) rings to SNP,
a NO donor, our further data with proteins from con-
tractile machinery provides information related with the
contribution of NO-related smooth muscle cell dysfunc-
tion onto the endothelium-intact aortic dysfunction. In
a supporting study [25], authors demonstrated that
RhoA/ROCK signaling pathway could directly suppress
NO-production in endothelium [10,26]. These findings
are also consistent with early occurence of endothelial
dysfunction in the course of diabetic vascular complica-
tions [17].
It is known that the vascular endothelium is the first
and fundamental part for vascular injury being a com-
mon target of hyperglycemia/insulin resistance related
risk factors as well [27]. Although many studies were
performed with several animal models, there are con-
flicts related with the vascular responses to contractile
agents in the diabetic subjects. Accordingly, some stud-
ies suggested increased sensitivity to noradrenaline [28],
whereas other studies, including our team’s studies,
reported an attenuated contractile response to noradren-
aline in the aortas from diabetic animals [14,15,18,29].
These studies mainly stated that the impaired contractile
responses to phenylephrine applications could be due
to a change in α-adrenergic receptor expression in therat thoracic aorta. (A) Representative Western Blots for phospho-
iabetic (DM) rat aorta homogenates. (B) MYPT1 and (C) Phospho-
sponding MYPT1 protein band, respectively. (E) Representative
ions from CON and DM rat aorta homogenates. (F) MLC and
lized to corresponding MLC protein band, respectively. Bars represent
student t-test).
Figure 6 Proposed mechanism accounting for signal
transduction pathways towards the role of RhoA/Rho-kinase
signaling in endothelium-dependent both contractile and
relaxation activities in thoracic aorta from diabetic rats.
See discussion for details. NO, nitric oxide; eNOS, endothelial nitric
oxide synthase; ROCK, RhoA/Rho-kinase, pMLC, phospho-myosin
light chain; pMLCP, phospho-MLC phosphatase.
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that the aortic preparations from diabetics showed an
impaired endothelium-dependent relaxation to acetyl-
choline [14,15,18,31]. Abnormalities in vessels of diabetic
subjects, basically with dysfunction in the microvascular
endothelial-barrier, are playing a critical role in the
pathogenesis of diabetes-induced vascular dysfunction
[27,30,31]. A member of the RhoA family, ROCK is the
first and their best-characterized effectors, which are re-
sponsible for the modulation of a wide range of cellular
functions including contraction. An important support
for this fact is given with the data, in which it has been
demonstrated an involvement of ROCK-dependent re-
arrangement of the actin cytoskeleton and changes of cell
contractility in the regulation of endothelial-permeability
[32,33]. Moreover, much more evidence indicates that ex-
pression and activity of eNOS are regulated by the RhoA/
ROCK pathway [34,35]. In addition, previously published
data also strongly indicated that activation of the RhoA/
ROCK pathway is a critical step towards the less endothe-
lial NO-production due to an alteration in the eNOS sys-
tem in the vasculature from diabetic subjects. Supporting
this statement, early and resent some important studies
have been shown that ROCK inhibition can induce im-
provement in diabetes- and hypertension-induced endo-
thelial dysfunction [10,26,36,37]. As can be seen from all
previously published data, although we did not examine
endothelial NO-production directly, a measurement of de-
crease phospho-eNOS (at Ser 1177) to total eNOS ratio
corresponds to a decreased level of NO-production in the
endothelium of diabetic rat aorta. As mentioned by Nunes
et al. [38], upregulation of RhoA/Rho-kinase pathway is a
key link among many diseases including diabetes [9,39,40].
We measured 2.5-fold higher ROCK isoform ROCK2
protein level in endo(+) aortic rings from the diabetic rats
compared to that of the control while its level in
endothelium-denuded (endo-) aortic rings was similar
among these two groups. Our present data also demon-
strated that ROCK inhibitors either Y27632 or HA1077 in-
duced concentration-dependent relaxation with a marked
left-shift in the phenylephrine pre-contracted endo(+) rings
from either diabetics or high glucose incubated controls
while pretreatment of these rings with L-NAME abolished
this shift, fully. In addition, we showed that the phosphor-
ylation levels of both MLCP and MLC in endo(−) aortic
rings were markedly higher in the diabetics than those of
the controls.
There are several targets identified for ROCK signaling
pathway including MLC and MLCP in the cardiovascular
system [26]. Considering the roles of RhoA-mediating sig-
naling in cellular functions as well as regulation of vascular
tone along with inflammation, hyperglycemia, and oxida-
tive stress, the inhibition of this pathway seems to have
significant clinical implications [41]. Smooth muscle cellstructure and endothelium-dependent/-independent sig-
naling pathways are main factors to control the mechanical
activity of vasculature. To demonstrate the hyperglycemia-
induced altered factors which contribute to the aortic ac-
tivity via endothelium, we performed relaxation responses
to a NO donor SNP in the endo(−) aortic rings from dia-
betics and compared them with those of the controls in
the absence or presence of ROCK inhibitor Y27632. The
similar responses among these two groups can strongly
support the role of decreased endothelial NO-production
on the upregulation of ROCK signaling pathway in the
smooth muscle cells under hyperglycemia. Although we
measured significantly high phosphorylation levels of both
MYPT1 and MLC in the diabetic endo(−) rings, these
higher phosphorylation levels of contractile proteins seem
to be not parallel to the results on relaxation responses of
diabetic or control endo(−) rings to SNP. As a point of
view, since this point seems to be contradictory event in
our preparations, the lack of basal phosphorylation effect
on SNP-induced relaxations, most probably corresponds to
no change in the dynamic range of ROCK activity in the
smooth muscle cells from diabetic samples. In addition,
Cicek et al. Cardiovascular Diabetology 2013, 12:51 Page 9 of 10
http://www.cardiab.com/content/12/1/51our data by measuring the force generation of diabetic
endo(+) aortic rings showed that inhibition in 1-μM
Y27632 on Phe-precontraction was significantly higher
than that of the control, which was similar among these
two groups in the presence of L-NAME. This result
does further support the fact of a presence of ROCK
upregulation signaling in diabetes due to decrease level
of NO-production in the endothelium. It is important to
note that we observed also similar effect with Y27632 in
the relaxation responses to the Phe-precontraction in
the high glucose incubated endo(+) rings. These data
confirm also strongly a possible role of ROCK activity in
the maintenance of agonist-induced force generation
and further also support the hypothesis on NO induces
the relaxation of vascular smooth muscle cells through
the inhibition of RhoA/ROCK–mediated contraction. In
here, hyperglycemia seems to be a direct ROCK agonist
besides its action via level of NO-production in endo-
thelium, which are also supported with previously pub-
lished data [8,26,39,42].
Numerous studies demonstrated an attenuation of
endothelium-dependent vasodilation in vasculature under
various pathological conditions, often being associated with
a decrease in NO bioavailability [41,43]. On the basis of
the results presented in here and in the light of previously
published data, it is possible to propose a pathway how this
signaling is working in our diabetic aortic preparations
(Figure 6): It seems hyperglycemia-induced upregulated
ROCK2 inhibits eNOS protein expression, which further
impairs the NO-release from endothelial cells. Less endo-
thelial NO-production, in turn, can result more activation
of ROCK signaling in vascular smooth muscle cells, leading
to a decrease in the relaxation responses in the aortic rings.
In another word, NO inhibits RhoA/ROCK constrictor
activity, which coincides with a decreased level of endo-
thelial NO-production, and/or another possibility of its
decreased bioavailability, leading to an increase in
RhoA/ROCK constrictor activity. Elevated ROCK activ-
ity may then mediate an increased vasoconstrictor
sensitivity observed in various animal models with car-
diovascular dysfunction [10,26,27,30,31,40].
As summary, the present data demonstrated that
diabetes-induced vascular dysfunction can arise due to
either inhibition of eNOS, thereby less endothelial NO-
production, either directly or indirectly, in part due to
an upregulation of ROCK2 by hyperglycemia. Addition-
ally, our data demonstrate that high phosphorylation
levels of both MLC and MLCP in endo(−) can be due to
a less endothelial NO-production dependent ROCK
upregulation in smooth muscle cells as well. Taken to-
gether, aortic dysfunction in diabetic subjects seems to
be associated with ROCK-mediated signaling pathways
via less endothelial NO-production in endothelium
which, in turn, results a ROCK-mediated signaling insmooth muscle cells under hyperglycemia. Taking to-
gether, our present data provide evidence for a role of
ROCK2 in diabetes-induced vascular dysfunction, being
a target in both endothelium and smooth muscle cells,
and therefore this signaling pathway may present a novel
therapeutic means for prevention of diabetes-induced
vascular dysfunction.
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